Table_5_A Novel Risk Defining System for Pediatric T-Cell Acute Lymphoblastic Leukemia From CCCG-ALL-2015 Group.docx
T-cell acute lymphoblastic leukemia (T-ALL) is a rare hematological malignancy with a poor prognosis. The present study aims to identify the precise risk grouping of children with T-ALL.
MethodsWe analyzed the outcomes for 105 consecutive patients treated using the Chinese Children’s Cancer Group ALL-2015 (CCCG-ALL-2015) protocol registered with the Chinese Clinical Trial Registry (ChiCTR-IPR-14005706) between 2015 and 2020 in our center. Nine out of 21 clinical and biological indicators were selected for the new scoring system based on the analysis in this study.
ResultsThe 5-year overall survival (OS), event-free survival (EFS), and disease-free survival (DFS) rates for the 105 patients were 83.1 ± 4.8%, 72.4 ± 5.6%, and 78.4 ± 3.6%, respectively. Based on the new scoring system, 90 evaluable children were regrouped into low-risk (n=22), intermediate-risk (n=50), and high-risk (n=18) groups. The 5-year survival (OS, EFS, and RFS) rates for all patients in the low-risk group were 100%, significantly higher than the rates for those in the intermediate-risk group (91.2 ± 5.2%, 74.4 ± 8.6%, and 82.5 ± 6.2%, respectively) and high-risk group (59.0 ± 13.2%, 51.9 ± 12.4%, and 51.9 ± 12.4%, respectively) (all P values < 0.01).
ConclusionThe CCCG-ALL-2015 program significantly improved the treatment outcomes for childhood T-ALL as compared with the CCCG-ALL-2008 protocol. Our new refined risk grouping system showed better stratification among pediatric T-ALL patients and better potential in evaluating therapeutic efficacy.
History
References
- https://doi.org//10.6004/jnccn.2019.0024
- https://doi.org//10.1111/ped.13457
- https://doi.org//10.1200/JCO.2018.77.7250
- https://doi.org//10.1200/JCO.2014.59.1636
- https://doi.org//10.1002/ajh.25124
- https://doi.org//10.1186/s12887-015-0390-z
- https://doi.org//10.1016/j.intimp.2021.107870
- https://doi.org//10.1038/s43018-020-00167-4
- https://doi.org//10.1038/s41467-021-24044-5
- https://doi.org//10.1182/blood.2020010081
- https://doi.org//10.1080/10428194.2020.1805739
- https://doi.org//10.1182/blood.2020010438
- https://doi.org//10.1016/S1470-2045(21)00328-4
- https://doi.org//10.1007/978-1-4939-6703-2_24
- https://doi.org//10.1007/s002770050494
- https://doi.org//10.3343/alm.2019.39.2.125
- https://doi.org//10.1186/s13045-017-0431-1
- https://doi.org//10.1002/gcc.22510
- https://doi.org//10.1002/bjs.10238
- https://doi.org//10.1080/08898489209525345
- https://doi.org//10.1038/nature12634
- https://doi.org//10.18632/oncotarget.2218
- https://doi.org//10.1038/leu.2013.336
- https://doi.org//10.1016/S1470-2045(10)70114-5
- https://doi.org//10.3324/haematol.2014.103507
- https://doi.org//10.1182/blood-2015-09-670729
- https://doi.org//10.1038/ng.3909
- https://doi.org//10.1038/nrclinonc.2015.38